S Korea forges ahead in stem cells as Medipost preps for first allogeneic therapy launch
This article was originally published in Scrip
Executive Summary
Medipost is planning to launch the stem cell therapy Cartistem in its home market of South Korea next month, giving further weight to the view that the country is moving forwards in a field that has been dogged elsewhere by controversy and funding problems.